Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE: Pegasys and Ribavirin in CHC
NCT00483938Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2007
- Primary completion
- May 2010
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2a in hepatitis C (HCV) (7 arms), sponsored by Roche. Primary endpoint: Sustained Virological Response. Started Jun 2007; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00483938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00483938.